— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation.
— Q4 revenue was flat at $1.2 million, vs. $920,000 expected.
— As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million.
— Launch of Sixmo may be delayed due to the impact of Covid-19.
— TTNP shares gained 4.4% during after-market trading hours.
Most Popular
Stitch Fix (SFIX) Stock: Will the innovative biz model survive virus-led slump?
The business world is still struggling to come out of the virus-induced slowdown, but it seems almost every retail segment benefited from the pandemic at some point. The vaccination drive
General Mills (GIS): Three factors that are expected to help drive growth for the food company going forward
Shares of General Mills Inc. (NYSE: GIS) were up 3.2% on Wednesday after the company delivered better-than-expected results for the first quarter of 2022. Net sales rose 4% year-over-year to
IPO Alert: Allvue Systems sets IPO terms, to raise around $290 million
It is estimated that the alternative investments industry has expanded at a compound annual rate of 10.2% over the past ten years and had $11 trillion in assets under management
